Lv11
44 积分 2024-09-24 加入
Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma
44分钟前
已关闭
Multicenter Real-World Analysis of Glofitamab in Relapsed/Refractory Primary CNS Lymphoma: Clinical Activity, CNS Penetration, and ctDNA Dynamics
45分钟前
已完结
Combination of CD20xCD3 Bispecific Antibodies with Ibrutinib and Lenalidomide Shows Efficacy in Relapsed/ Refractory CNS Lymphoma
46分钟前
已关闭
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults
2个月前
已完结
维布妥昔单抗联合化疗治疗儿童难治及复发霍奇金淋巴瘤10例分析
2个月前
已完结
Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study
2个月前
已完结
Epigenetic agents plus anti-PD-1 reshapes tumor microenvironment and restores antitumor efficacy in Hodgkin lymphoma
3个月前
已完结
HL-642 Does Interim PET Assessment After Two Cycles of Treatment With Brentuximab Vedotin Still Have a Predictive Value in Hodgkin Lymphoma?
4个月前
已完结
Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab for Relapsed/Refractory NK/T-Cell Lymphoma
8个月前
已完结
皖公网安备34019202002308
